E25Bio, a Cambridge, Mass.-based provider of rapid, point-of-care, diagnostic technology, raised $2.3m in seed funding.
The round was led by The Engine, with participation from Alumni Ventures Group and angel investor Alejandro Chavez.
Founded in 2018 by Jeff Takle, CEO, based on technology developed by
Drs. Irene Bosch and Lee Gehrke and licensed from MIT, E25Bio is
developing rapid diagnostic test technology for at-home-use that can
detect dangerous infectious diseases such as the acute febrile illnesses
in minutes instead of days.
The first product is an over-the-counter test for patients appearing with fever, which is able to screen for active viruses and enables a more rapid and accurate diagnosis of infectious diseases in time to receive potentially life-saving treatment.
E25Bio has completed clinical studies and has initiated regulatory submission in its first target geographies.
Source. FinSMEs, August 26, 2010,
***
This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications,
public relations & investor relation services to Canadian VCs, PEs,
Angels, Endowments/Trusts, Family Offices, and Canadian startups
involved in ICT, IoT, blockchain, life sciences, healthcare,
agribusiness, clean energy, fintech, AI and robotics.
Are
you a Canadian GP/LP/CI or a Canadian startup that needs to grow or
scale? Give us a call! One of our representatives would love to explain
how we vertically design, and then systematically layer each of our
communication platforms to effectively reach niche target audiences for
our clients. WC offers a unique synergistic approach to effectively
communicate our client's message to their target audience.
Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.
No comments:
Post a Comment